Attorney Docket No. VPI/02-137 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

lication	

10/808,678

Confirmation No.:

6199

Filing Date:

March 25, 2004

Examiner:

Not Yet Assigned

or

Group art unit:

1632

Applicants:

Green et al.

For:

COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES

February 9, 2005 Cambridge, Massachusetts

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

(a)

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Pursuant to Rule 56, it is requested that the documents listed on the accompanying

			and made of record in the above-identified patent application. 32, C1-C9 are attached.
(b)	\boxtimes	No fee	e is believed due because:
			The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
			The Information Disclosure Statement is being concurrently filed with the above-identified application.
			The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
		\boxtimes	The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
(c)		date o	nformation Disclosure Statement is being filed before the mailing of any final action, notice of allowance or an action that otherwise prosecution; and
			Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement;


Applicants: Application No.:	Green et a 10/808,67	
		No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
		The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
(d)		information Disclosure Statement is being filed on or before the ent of the issue fee; and
		Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
		No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
		The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
the Inform	nation Disc	by authorized to charge any additional fees that may be required for losure Statement, or credit any overpayment to Deposit Account No. CATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

Michael C. Badia, Reg. No. 51,424

Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6483

Fax: (617) 444-6483



Application Number	10/808,678	
Filing Date	March 25, 2004	
First Named Inventor	Jeremy Green	
Group Art Unit	1632	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	VPI/02-137 US	

				U.S. PATENT DOCUMENTS			
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,733,920	Mar. 31, 1998	Mansuri et al.			

B1 WO 01/53266 Thrombogenix Pty Ltd.	
B1 WO 01/53266 Thrombogenix Pty Ltd.	26 July 2001
B2 WO 98/17662 Novartis Ag	30 April 1998


		OTHER NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Edwards et al., "Antineoplastic Activity and Cytotoxicity of Flavones, Isoflavones, and Flavanones", Abstract XP-009035912, J. of Natural Products, Pages 85-91, 1979.
	C2	Database Chemabs, "Amino Acid Derivatives and Oximes of Flavones" Abstract XP-002295239, Chem. Of Heterocyclic Compounds, 2002.
	C3	Database Chemabs, "Benzo-gammapyrones. Part XIV. Reaction of C-substituted 2-phenyl-4H-1-benzopyran-4-ones with hydroxylamine", Abstract XP-002295240, Polish J. of Chem., 1991.
	C4	Sen et al., "Search for New Antimalarials. Part V. Synthesis of Some 8-aminoalkylamino- and 8-dialkylaminoalkylamino- chromones", Abstract XP-009035940, J. of the Indian Chem. Soc., Calcutta, Pages 217-222, 1960.
	C5	Weng, Lingling, et al., Database Chemabs, "Preparation of Isoflavone Alicyclic Ethers and Oxime Derivatives", Abstact XP-002295241, Materia Medica Inst., Huaxi Med. College, Peop. Rep. China, 1993.
	C6	Beugelmans et al., "Action of Hydroxylamine on Chromone and Khellin. Oxime vs. Isoxazoles Structures", XP-002295236, J. of Organic Chem., Vol. 42, No. 8, Pages 1356-1360, 1977.
	C7	Database Chemab, "Thiazole Analogs of Isoflavones", Abstact XP-002295242, Khimichni ta Biologichni Nauki, 1980.
	C8	Spatz et al., "7,2',4'-Trimethoxyflavone", J. of Organic Chem., Abstract XP-002295237, Vol. 24, No. 9, Pages 1381-1382, 1959.
	C9	Eiden et al., "Uber die Reaktion Von Hydroxylamin Mit 2,6-Dimethyl-3-Acetylchromon", Tetrahedron Letters, Abstract XP-002295238, Vol. 17, Pages 1439-1442, 1970.

* a copy of this reference is not provided as	it was previously cited by or submitted to the office in a prior application,
	, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation,
continuation-in-part, and divisional applicat	

Examiner Signature Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

On .	February 9, 2005
	Date

- 1. Information Disclosure Statement (3 pages, in duplicate);
- 2. PTO-1449 Form (1 page, in duplicate);
- 3. Cited References (A1; B1-B2; C1-9); and
- 4. This Return Postcard Receipt.

Signature

Karen DiRocco

Typed or printed name of person signing Certificate